<DOC>
	<DOC>NCT00048581</DOC>
	<brief_summary>The purpose of this clinical research study is to determine whether abatacept treatment on a background of Disease Modifying Antirheumatic Drugs (DMARDs) will relieve the symptoms of rheumatoid arthritis (RA) in participants who are currently receiving anti-tumor necrosis factor (TNF) therapy for at least 3 months and are not responding or have taken anti-TNF therapy in the last 3 months and did not respond. The safety of treatment with abatacept will also be evaluated. This study also has a 4.5-year long-term extension beginning 6 months after the start of the study.</brief_summary>
	<brief_title>Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Eligibility Criteria: Active rheumatoid arthritis currently failing antiTNF therapy or have failed antiTNF therapy in the past. Women who are pregnant or breast feeding Current symptoms of serious medical disease History of cancer in last 5 years other than nonmelanoma skin cancer Chronic serious infection Active TB requiring treatment in last 5 years Herpes zoster in last 2 months Any active viral infection including Human Immunodeficiency Virus (HIV) Serious side effects associated with previous antiTNF therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>